Current and historical daily PE Ratio for VAXX (
Vaxxinity Inc
) from 2021 to May 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Vaxxinity stock (VAXX) PE ratio as of May 20 2024 is 0.
More Details
Vaxxinity Inc (VAXX) PE Ratio (TTM) Chart
Vaxxinity Inc (VAXX) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 633
- 1
- 2
- 3
- 4
- 5
- 6
- 8
| Vaxxinity PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-20 | At Loss | 2024-03-15 | At Loss |
| 2024-05-17 | At Loss | 2024-03-14 | At Loss |
| 2024-05-16 | At Loss | 2024-03-13 | At Loss |
| 2024-05-15 | At Loss | 2024-03-12 | At Loss |
| 2024-05-14 | At Loss | 2024-03-11 | At Loss |
| 2024-05-13 | At Loss | 2024-03-08 | At Loss |
| 2024-05-10 | At Loss | 2024-03-07 | At Loss |
| 2024-05-09 | At Loss | 2024-03-06 | At Loss |
| 2024-05-08 | At Loss | 2024-03-05 | At Loss |
| 2024-05-07 | At Loss | 2024-03-04 | At Loss |
| 2024-05-06 | At Loss | 2024-03-01 | At Loss |
| 2024-05-03 | At Loss | 2024-02-29 | At Loss |
| 2024-05-02 | At Loss | 2024-02-28 | At Loss |
| 2024-05-01 | At Loss | 2024-02-27 | At Loss |
| 2024-04-30 | At Loss | 2024-02-26 | At Loss |
| 2024-04-29 | At Loss | 2024-02-23 | At Loss |
| 2024-04-26 | At Loss | 2024-02-22 | At Loss |
| 2024-04-25 | At Loss | 2024-02-21 | At Loss |
| 2024-04-24 | At Loss | 2024-02-20 | At Loss |
| 2024-04-23 | At Loss | 2024-02-16 | At Loss |
| 2024-04-22 | At Loss | 2024-02-15 | At Loss |
| 2024-04-19 | At Loss | 2024-02-14 | At Loss |
| 2024-04-18 | At Loss | 2024-02-13 | At Loss |
| 2024-04-17 | At Loss | 2024-02-12 | At Loss |
| 2024-04-16 | At Loss | 2024-02-09 | At Loss |
| 2024-04-15 | At Loss | 2024-02-08 | At Loss |
| 2024-04-12 | At Loss | 2024-02-07 | At Loss |
| 2024-04-11 | At Loss | 2024-02-06 | At Loss |
| 2024-04-10 | At Loss | 2024-02-05 | At Loss |
| 2024-04-09 | At Loss | 2024-02-02 | At Loss |
| 2024-04-08 | At Loss | 2024-02-01 | At Loss |
| 2024-04-05 | At Loss | 2024-01-31 | At Loss |
| 2024-04-04 | At Loss | 2024-01-30 | At Loss |
| 2024-04-03 | At Loss | 2024-01-29 | At Loss |
| 2024-04-02 | At Loss | 2024-01-26 | At Loss |
| 2024-04-01 | At Loss | 2024-01-25 | At Loss |
| 2024-03-28 | At Loss | 2024-01-24 | At Loss |
| 2024-03-27 | At Loss | 2024-01-23 | At Loss |
| 2024-03-26 | At Loss | 2024-01-22 | At Loss |
| 2024-03-25 | At Loss | 2024-01-19 | At Loss |
| 2024-03-22 | At Loss | 2024-01-18 | At Loss |
| 2024-03-21 | At Loss | 2024-01-17 | At Loss |
| 2024-03-20 | At Loss | 2024-01-16 | At Loss |
| 2024-03-19 | At Loss | 2024-01-12 | At Loss |
| 2024-03-18 | At Loss | 2024-01-11 | At Loss |
Vaxxinity Inc (VAXX) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Vaxxinity Inc
NAICS : 541714
SIC : 2834
ISIN : US92244V1044
Share Class Description:
VAXX: Class ADescription
Vaxxinity Inc is a biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company's proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer's, Parkinson's, migraine, and hypercholesterolemia.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers